Lung cancer causes more deaths worldwide than any other cancer with most patients presenting with incurable metastatic disease. Mesenchymal stem cell tumour tropism presents us with an interesting mechanism of delivering potent therapies locally to cancers. Genetic modification of MSCs enables continued delivery of selective anticancer treatments such as TRAIL. While this is an attractive therapeutic option, translating such a therapy into patients presents challenges both in manufacture and delineation of dose and dosing strategy. However, successful delivery of a combined cell-gene therapy in lung cancer may offer promise to thousands of individuals largely resigned to poorly effective palliative treatments.
Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide, with a 5-year survival of approximately 6% [1] . Around 80% of these are of non-small cell (NSCLC) histological type for which surgical resection or radical chemo-radiotherapy offers the best prospect of cure. The vast majority of cases however are diagnosed at an advanced stage, and therapy options are limited. Although, cisplatin-based chemotherapy trials in this group show a clear survival benefit over supportive care alone, the actual increase in median survival is small (4 vs 5.5 months) [2] .
The landscape of treating stage IV disease changed around a decade ago with the discovery of the epidermal growth factor receptor (EGFR) mutations [3] . These were found in lung adenocarcinoma and were associated with a favorable response to EGFR tyrosine kinase inhibitors (TKIs). Whilst new targeted therapies have been introduced in routine clinical practice, they are only suitable for a low percentage of patients and outside of this outlook has changed little [3] . A better understanding of genetic changes in NSCLC have pushed the development of novel treatments for oncogenic drivers or actionable mutations as identified by preclinical evidence. However, only a small number of patients will benefit.
Novel therapies are needed and we have developed a cell and gene therapy for the treatment of metastatic lung cancer. In this article we discuss some hurdles we face as we take our product into man in our recently funded phase I/II randomised trial, TACTICAL (Targeted stem cells expressing TRAIL as a therapy for lung cancer).
Choosing an anti-cancer therapy
The majority of patients with stage IV lung cancer will receive a platinum-based chemotherapy, with or without radiotherapy for palliative intent [3] . Chemotherapy is a non-targeted treatment that exhibits significant side-effects and toxicity whilst causing damage to healthy organs. The 3 characteristics of an ideal anticancer treatment should exhibit minimal systemic toxicity, and accurately target and kill only transformed cells, in both primary and metastatic sites.
Tumour necrosis factor related apoptosis inducing ligand (TRAIL) is a protein that causes cellular apoptosis in a pathway independent of p53 [4] . It is particularly attractive as a cancer therapy since it is able to selectively trigger apoptosis in transformed cells, leaving healthy cells unharmed. TRAIL works through the extrinsic apoptosis pathway (see figure 1 ), however some cross-talk does occur with the intrinsic system that responds to cellular stress, p53 activation and DNA damage [5] .
Despite the promising results of recombinant TRAIL in vitro, failure in human trials when delivered intravenously have been attributed to its half-life of around 30 minutes. Investigators have since altered TRAIL to improve its therapeutic performance through 'tagging' with another protein to increase its size, or using a PEGylated form with protracted half-life and efficacy [5] . Monoclonal antibodies (MAbs) to TRAIL receptors have also been investigated, however, the presence of TRAIL decoy receptors and recruitment of immune have again led to disappointing results. Both recombinant TRAIL and monoclonal antibodies do not cross the blood-brain barrier, further limiting their use in the presence of lung cancer metastases. Therefore, ideally one would deliver TRAIL using a vehicle that homes to and resides at the site of the tumour, delivering a consistent dose of therapy. We and others have successfully used human bone marrow derived adult mesenchymal stem cells to deliver TRAIL as an anti-cancer therapy [6] .
[ Figure 1 near here]
Mesenchymal stem cells: a vehicle to deliver anticancer therapies
Stem cells are undifferentiated and have capacity for unlimited self-renewal, and multi-or pluripotent differentiation. Mesenchymal stromal stem cells (MSCs) are one of the best characterized adult stem cells and have emerged as attractive candidates for cell therapies. They are 4 present in virtually all tissues and can be derived from umbilical cord blood, adipose tissue, or most commonly, bone marrow [7] . MSCs have a direct immunosuppressive effect, which has been exploited in clinical studies over the last decade to treat graft versus host disease and other immunologically mediated conditions including acute and chronic pulmonary disease [4] . These studies have demonstrated that MSCs are safe, and low immunogenicity has obviated the need for human leukocyte antigen (HLA) matching of allogeneic cells [4] .
MSCs have multiple characteristics that make them attractive as a cell therapy for cancer (see table   1 ). The key feature being their ability to home to and engraft into tumours. Hence, they have potential to be used as a 'Trojan Horse' to deliver anti-cancer therapies. MSCs express chemokine receptors and cell adhesion molecules that aid in migration and homing to target tissues. Similar to leucocytes, MSCs may undergo both passive and active homing and chemotaxis is thought to be largely dependent on CXCR4, which binds to CXCL12, which is known to be overexpressed at tumour sites. In lung cancer we have demonstrated overexpression of macrophage inhibitory factor (MIF), which also binds CXCR4 maybe a key modulator of MSC tumour tropism [8] .
MSCs have been modified and used as therapeutic vectors in several diseases [9] . In cancer, they have been successfully transduced with interferon-γ, interferon-β, thymidine kinase, or CX3CL1 expressing vectors [4] resulting in effective inhibition of tumor growth in preclinical studies. One of the first trials in man will use MSCs genetically modified with herpes simplex virus thymidine kinase (HSV-tk) that activates pro-drug Ganciclovir [10] . This is a single-arm phase I/II study that will assess safety and efficacy of this treatment for advanced gastrointestinal cancers.
Our group has produced and used MSCs that have been stably transfected with vectors containing a gene construct of TRAIL [6] . We have shown that this genetically modified cell therapy leads to either complete elimination or reduction of tumour growth when delivered intravenously in models of lung metastasis and mesothelioma. Despite the pre-clinical promise of gene and cell therapy there are a number of challenges to overcome before a product is ready for clinical use, from gene 5 transfer, to culture expansion of a clinical grade product and tracking the cells once delivered.
[ Table 1 
Mesenchymal stem cells: manufacture & release criteria
MSCs constitute 0.002% of the bone marrow total stromal cell population [11] . Their classification is specified in the position paper by Dominici et al for the International Society for Cellular Therapy (ISCT) [12] . Although, MSCs are readily expandable up to 50 population doublings in 10 weeks, it has been suggested that in the clinic population doubling is kept below 20 for safety and efficacy [13] . Translating the product to the bedside requires strict compliance with regulations set out by the European Medicine Agency (EMA). This requires development of release criteria for a product before it is taken to the bedside. With there being a clear consensus on cell surface markers to identify MSCs and regulation of GMP facilities; the tripartite component of these criteriaidentification, viability and sterility of MSCs pose little controversy [14] . However, some of the other challenges are summarized in table 2. The efficacy of MSCs should also be measured, using assays predictive of potency for its intended clinical application. The ISCT recently published their perspective on immune functional assays for MSCs as potency criteria [14] . Whilst there is limitation in defining the attributes of MSCs used in immune disorders, cells with a transferred gene often have a clearer read-out of potency.
Tracking MSCs in man
Optimal strategies for identifying the fate of MSCs following systemic infusion remain unclear.
Although use of optical imaging to measure fluorescent and bioluminescent reporters has been successful in small animals, there is limitation with its depth of penetration when it comes to humans [15] . Magnetic resonance imaging used to detect stem cells loaded with superparamagnetic compounds are under investigation. However, positron emission tomography (PET) is likely to be at the forefront of cell imaging with development of new contrast agents. Investigators have combined HSV-tk with radioisotopes to image at high-resolution [15] . However, direct labelling of stem cells using novel radioisotopes may prove useful in tracking the fate of MSCs over longer periods of time, determining dosing schedules and in identifying any 'off-target' affects.
[ Table 2 near here] Adapted from reviews on use of MSCs as engineered cell-therapies [4, 15] .
Expert Opinion
BM=bone marrow, PD=population doubling, MSC=mesenchymal stem cell, GvHD=graft-versus host disease, HSV-tk=herpes simplex virus-thymidine kinase, TRAIL= Tumour necrosis factor related apoptosis inducing ligand. 
